首页> 美国卫生研究院文献>Applied Translational Genomics >Pharmacogenomics Theranostics and Personalized Medicine - the complexities of clinical trials: challenges in the developing world
【2h】

Pharmacogenomics Theranostics and Personalized Medicine - the complexities of clinical trials: challenges in the developing world

机译:药物基因组学治疗学和个性化医学-临床试验的复杂性:发展中世界的挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

While the potential for the application of pharmacogenomics and theranostics to develop personalized healthcare solutions is enormous, multiple challenges will need to be addressed to get there. Understanding the complex interactions and detailed characterization of the functional variants of individual ADME (Absorption Distribution Metabolism Excretion) genes and drug target genes is needed to demonstrate clinical utility, using both a bottoms-up as well as a top–down approach. Clinical trials need to be designed appropriately so as to identify not only individual but also population variations. The impact of non-genetic and environmental factors, epigenetic variations and circadian rhythms on an individual's response need to be assessed to make pharmacogenomics clinically indicated. More advanced algorithms and appropriate study designs need to be developed to allow this pipeline to grow and to be used effectively in the clinical setting.Another challenge lies in the value proposition to the pharmaceutical industry. Fearing the impact of the slice and dice approach on revenues, companies are going slow on developing pharmacogenomic solutions; yet many are hedging their bets, amassing huge amounts of single nucleotide polymorphisms (SNP) data. They are being used as predictors of drug efficacy and safety to zero in on subpopulations that are at risk for either a bad response or no response in clinical trials, supporting the Fail fast, Fail cheap approach. In addition, the growth of theranostics is impeded by the fear that the approval of both the diagnostic and the drug would get delayed. Education of the health care provider, payor, regulator and the patient is also required and an exercise of change management needs to occur.Countries such as India should exploit the joint benefit of the reduced cost of tests today, complemented by a large and a highly genetically diverse population.
机译:尽管应用药物基因组学和治疗学方法开发个性化医疗保健解决方案的潜力巨大,但要实现这一目标,还需要解决多个挑战。需要使用自下而上和自上而下的方法来了解单个ADME(吸收分布代谢排泄)基因和药物靶标基因的功能相互作用的复杂相互作用和详细表征,以证明其临床实用性。需要适当设计临床试验,以便不仅识别个体,而且识别人群变异。需要评估非遗传和环境因素,表观遗传变异和昼夜节律对个体反应的影响,以使药物基因组学临床应用。需要开发更高级的算法和适当的研究设计,以使这一流程不断发展并在临床环境中有效使用。另一个挑战在于制药行业的价值主张。由于担心切片法对收入的影响,公司在开发药物基因组学解决方案方面进展缓慢。然而,许多人在押注自己的赌注,积累了大量的单核苷酸多态性(SNP)数据。在临床试验中有不良反应或无反应风险的亚人群中,它们被用作药物功效和安全性为零的预测指标,支持快速失败,廉价失败方法。此外,担心诊断药和药物的批准都将被推迟,这阻碍了治疗药的发展。还需要对医疗保健提供者,付款人,监管者和患者进行教育,并且需要进行变更管理。印度等国家应该利用当今降低的测试成本所带来的共同利益,并辅以庞大而高度遗传多样性的人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号